Enrollment is now complete in two Phase 3 clinical trials testing vidofludimus calcium in adults with relapsing forms of ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 ...

Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an ...

Adial refines Phase 3 plans for AD04 in Alcohol Use Disorder, focusing on genetic subgroups and leveraging Cytel's advanced trial design expertise.

TuHURA Biosciences advances its phase 3 trial of IFx-2.0 for Merkel cell carcinoma, aiming to enhance immune response ...

An international clinical trial, led in the UK by Swansea’s Joint Clinical Research Facility (JCRF), has found that ...

Data-Driven, Adaptive Trial Design: Adial partnered with Cytel to apply advanced statistical analytics and simulation ...

In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

Late-breaking data reveal durable improvements in joint, skin, and quality of life outcomes with deucravacitinib.

GC Biopharma, a South Korean pharmaceutical company, announced that the Phase 3 clinical trial results for Hunterase ...

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...

Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. The ...